Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Edwards Lifesciences (NYSE:EW) Rating Lowered to Hold at Wall Street ...

AI-generated analysis

📉 Wall Street Zen downgraded Edwards Lifesciences from 'Buy' to 'Hold', adding to a mixed analyst landscape.

📈 TD Cowen reiterated a 'Buy' rating and raised the price target to $104.00, while Barclays set a target of $110.00.

💰 The company reported Q2 EPS of $0.78, surpassing the consensus estimate of $0.73.

📊 Revenue reached $1.65 billion, representing a 16.7% increase compared to the prior year period.

🔮 Management guided for FY 2026 EPS between $2.95 and $3.05.

👤 SVP Andrew Dahl sold 568 shares worth approximately $48,893 in a pre-arranged transaction.

👤 VP Daniel Lippis sold 619 shares worth approximately $56,576 under a Rule 10b5-1 plan.

📉 Insiders have collectively sold 58,977 shares valued at over $4.9 million in the last ninety days.

🏦 Institutional investors maintain a dominant stake, owning 79.46% of the company's float.

🔬 Edwards focuses on structural heart disease therapies, including transcatheter aortic valve replacement (TAVR) technologies.

Bullish Signals
  • Edwards Lifesciences beat quarterly earnings expectations with $0.78 EPS versus the consensus of $0.73.
  • Revenue grew significantly by 16.7% year-over-year to reach $1.65 billion.
  • The company provided robust full-year guidance for FY 2026, projecting EPS between $2.95 and $3.05.
  • TD Cowen raised its price target to $104.00 and maintained a 'Buy' rating on the stock.
  • Barclays reiterated an 'Overweight' rating with a higher price target of $110.00.
Risk Factors
  • Wall Street Zen downgraded the stock from 'Buy' to 'Hold', signaling caution among some analysts.
  • Senior executives, including SVP Andrew Dahl and VP Daniel Lippis, sold shares totaling over $4.9 million in the last ninety days.
  • The average analyst price target of $96.39 is below the recent highs set by individual firms like Barclays.
Full Analysis
Edwards Lifesciences (NYSE:EW) received a rating downgrade to 'Hold' from Wall Street Zen, contrasting with mixed signals from other major firms like TD Cowen and Barclays which maintained buy ratings or raised price targets. The consensus average rating remains 'Moderate Buy' with a target price of $96.39, though recent analyst actions reflect divergent views on the stock's immediate trajectory. The company reported strong financial results for the quarter ended April 23rd, beating earnings estimates with $0.78 EPS and revenue of $1.65 billion, a 16.7% year-over-year increase. Management provided forward guidance for FY 2026 EPS between $2.95 and $3.05, indicating continued growth expectations despite the mixed analyst sentiment. Insider trading activity shows net selling by senior executives, including SVP Andrew Dahl and VP Daniel Lippis, who reduced their holdings under pre-arranged plans over the last ninety days. While institutional ownership remains high at 79.46%, these insider sales suggest caution among company leadership regarding current valuation levels.